WO2017032815A3 - Biomarqueurs pour maladies cardiométaboliques - Google Patents

Biomarqueurs pour maladies cardiométaboliques Download PDF

Info

Publication number
WO2017032815A3
WO2017032815A3 PCT/EP2016/070011 EP2016070011W WO2017032815A3 WO 2017032815 A3 WO2017032815 A3 WO 2017032815A3 EP 2016070011 W EP2016070011 W EP 2016070011W WO 2017032815 A3 WO2017032815 A3 WO 2017032815A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
masp
adipoq
amount
mrna
Prior art date
Application number
PCT/EP2016/070011
Other languages
English (en)
Other versions
WO2017032815A2 (fr
Inventor
Christine VON TÖRNE
Stefanie M. HAUCK
Cornelia HUTH
Barbara THORAND
Tonia DE LAS HERAS GALA
Original Assignee
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) filed Critical Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Publication of WO2017032815A2 publication Critical patent/WO2017032815A2/fr
Publication of WO2017032815A3 publication Critical patent/WO2017032815A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé pour identifier une prédisposition au développement du diabète sucré de type 2 chez un sujet, ou pour produire une valeur à visée d'information diagnostique concernant la quantité d'une ou de plusieurs protéines ou d'un ou de plusieurs ARNm codant ladite ou lesdites protéines pour identifier une prédisposition au développement d'un diabète sucré de type 2, ledit procédé comprenant ou étant constitué de (i) l'évaluation dans un échantillon obtenu auprès dudit sujet de la quantité d'un ou de plusieurs protéines et/ou d'un ou de plusieurs ARNm codant ladite ou lesdites protéines, ladite ou lesdites protéines étant choisies dans un groupe de protéines défini dans ce qui suit, et (ii) la détermination des paramètres dudit sujet, dans lequel (a) lesdits paramètres sont l'âge et le sexe, et ledit groupe est constitué de AP0C2, AP0C3, APOE, CRP, MASP-1, ADIPOQ, ΙΤΊΗ4 et SHBG; (b) lesdits paramètres sont l'âge, le sexe et l'IMC, et ledit groupe est constitué de AP0C2, AP0C3, APOE, MASP-1, ADIPOQ, ITIH4, PZP et SHBG; ou (c) lesdits paramètres sont l'âge, le sexe, l'IMC, le statut de tabagisme, la consommation d'alcool, l'inactivité physique, l'hypertension réelle, les teneurs en triacylglycérol transformées en log10 et le rapport cholestérol total/HDL-cholestérol transformé en log10 et ledit groupe est constitué de MASP-1, ADIPOQ, ITIH4, ORM1 et PZP; dans lequel une augmentation de la quantité d'APOC2, APOC3, APOE, de CRP ou de MASP-1 ou d'un ARNm codant APOC2, APOC3, APOE, CRP ou MASP-1 ou une diminution de la quantité d'ADIPOQ, ITIH4, SHBG, PZP ou ORM1 ou d'un ARNm codant ADIPOQ, ITIH4, SHBG, PZP ou ORM1 par rapport à la quantité de ladite ou desdites protéines ou dudit ou desdits ARNm, respectivement, d'un témoin, indique une prédisposition à développer un diabète sucré de type 2.
PCT/EP2016/070011 2015-08-24 2016-08-24 Biomarqueurs pour maladies cardiométaboliques WO2017032815A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15182201.2 2015-08-24
EP15182201 2015-08-24

Publications (2)

Publication Number Publication Date
WO2017032815A2 WO2017032815A2 (fr) 2017-03-02
WO2017032815A3 true WO2017032815A3 (fr) 2017-05-04

Family

ID=54007573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/070011 WO2017032815A2 (fr) 2015-08-24 2016-08-24 Biomarqueurs pour maladies cardiométaboliques

Country Status (1)

Country Link
WO (1) WO2017032815A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110234998A (zh) * 2016-07-21 2019-09-13 克利夫兰心脏实验室公司 Hdl相关蛋白质生物标记物组的检测
CN107024590A (zh) * 2017-03-13 2017-08-08 新疆医科大学 一种诊断1型和2型糖尿病的血清蛋白标志物组
KR102140321B1 (ko) * 2018-10-04 2020-07-31 한국과학기술원 Tsp1 단백질 억제제를 유효성분으로 함유하는 파브리 병의 예방 또는 치료용 약학적 조성물
AU2021205932A1 (en) * 2020-01-10 2022-07-14 Somalogic Operating Co., Inc. Methods of determining impaired glucose tolerance

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064901A2 (fr) * 2007-11-13 2009-05-22 Veridex, Llc Biomarqueurs diagnostiques du diabète

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064901A2 (fr) * 2007-11-13 2009-05-22 Veridex, Llc Biomarqueurs diagnostiques du diabète

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALTAN ONAT ET AL: "-482C>T polymorphism, circulating apolipoprotein C-III and smoking: Interrelation and roles in predicting type-2 diabetes and coronary disease", CLINICAL BIOCHEMISTRY, ELSEVIER INC, US, CA, vol. 44, no. 5, 13 December 2010 (2010-12-13), pages 391 - 396, XP028366827, ISSN: 0009-9120, [retrieved on 20101223], DOI: 10.1016/J.CLINBIOCHEM.2010.12.009 *
ANNE HIUKKA ET AL: "Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes", DIABETOLOGIA ; CLINICAL AND EXPERIMENTAL DIABETES AND METABOLISM, SPRINGER, BERLIN, DE, vol. 48, no. 6, 1 June 2005 (2005-06-01), pages 1207 - 1215, XP019322561, ISSN: 1432-0428, DOI: 10.1007/S00125-005-1753-Z *
KOLBERG JANICE A ET AL: "Biomarkers in Type 2 diabetes: improving risk stratification with the PreDx (R) Diabetes Risk Score", EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, EXPERT REVIEWS LTD, GB, vol. 11, no. 8, 1 November 2011 (2011-11-01), pages 775 - 792, XP009190929, ISSN: 1744-8352, DOI: 10.1586/ERM.11.63 *
L. JENNY ET AL: "Plasma levels of mannan-binding lectin-associated serine proteases MASP-1 and MASP-2 are elevated in type 1 diabetes and correlate with glycaemic control", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 180, no. 2, 14 May 2015 (2015-05-14), GB, pages 227 - 232, XP055356240, ISSN: 0009-9104, DOI: 10.1111/cei.12574 *
S. BÉLIARD ET AL: "Parallel increase of plasma apoproteins C-II and C-III in Type 2 diabetic patients", DIABETIC MEDICINE., vol. 26, no. 7, 1 July 2009 (2009-07-01), GB, pages 736 - 739, XP055322154, ISSN: 0742-3071, DOI: 10.1111/j.1464-5491.2009.02757.x *
SABANAYAGAM C ET AL: "Serum C-reactive protein level and prediabetes in two Asian populations", DIABETOLOGIA ; CLINICAL AND EXPERIMENTAL DIABETES AND METABOLISM, SPRINGER, BERLIN, DE, vol. 54, no. 4, 26 January 2011 (2011-01-26), pages 767 - 775, XP019888877, ISSN: 1432-0428, DOI: 10.1007/S00125-011-2052-5 *
TOERNE CHRISTINE VON ET AL: "MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: the KORA F4 study", DIABETOLOGIA, SPRINGER, BERLIN, DE, vol. 59, no. 9, 25 June 2016 (2016-06-25), pages 1882 - 1892, XP036020160, ISSN: 0012-186X, [retrieved on 20160625], DOI: 10.1007/S00125-016-4024-2 *
V. FRAUENKNECHT ET AL: "Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 173, no. 1, 6 July 2013 (2013-07-06), GB, pages 112 - 120, XP055356242, ISSN: 0009-9104, DOI: 10.1111/cei.12093 *
VEIKKO SALOMAA ET AL: "Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes", PLOS ONE, vol. 5, no. 4, 9 April 2010 (2010-04-09), pages e10100, XP055106003, DOI: 10.1371/journal.pone.0010100 *

Also Published As

Publication number Publication date
WO2017032815A2 (fr) 2017-03-02

Similar Documents

Publication Publication Date Title
WO2017032815A3 (fr) Biomarqueurs pour maladies cardiométaboliques
Janes An analysis of critical factors for quantitative immunoblotting
Shen et al. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry
Bernardi et al. The MELD score in patients awaiting liver transplant: strengths and weaknesses
Liu et al. Salivary glycopatterns as potential biomarkers for screening of early-stage breast cancer
Wei et al. Serum GP73, a marker for evaluating progression in patients with chronic HBV infections
Kumar et al. Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth
Jabaudon et al. Soluble forms and ligands of the receptor for advanced glycation end-products in patients with acute respiratory distress syndrome: an observational prospective study
JP6198752B2 (ja) 胃癌のバイオマーカー及びその使用
NO20064226L (no) mRNA-profering i spytt, biomarkorer og beslektede fremgangsmater og sett av deler
WO2009006323A3 (fr) Procédés et combinaisons de marqueurs pour le dépistage d'une prédisposition à un cancer du poumon
WO2007059065A3 (fr) Procédé diagnostique d'états cardiovasculaires et de pré-eclampsie par mesure de paires de liaisons protéiques
WO2006113245A3 (fr) Procedes de mesure des niveaux de glycane dans des proteines
Komorowsky et al. Perspectives on systems biology applications in diabetic kidney disease
Qin et al. High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques
EP2861989A2 (fr) Biomarqueurs utilisés pour prédire ou détecter précocement la pré éclampsie et/ou le syndrome de hellp
WO2018060739A8 (fr) Dosage pour distinguer un sepsis d'un syndrome de réponse inflammatoire systémique
Zeindl-Eberhart et al. Epithelial-mesenchymal transition induces endoplasmic-reticulum-stress response in human colorectal tumor cells
Mookerjee Prognosis and biomarkers in acute-on-chronic liver failure
RU2019103403A (ru) Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью
WO2009141352A3 (fr) Analyse de risque chez des patients avec ou sans syndrome métabolique
Yao et al. Elevated serum soluble ST2 levels may predict the fatal outcomes in patients with chronic heart failure
Hennings et al. Circulating angiopoietin-2 and its soluble receptor Tie-2 concentrations are related to renal function in two population-based cohorts
Hansen et al. Finding diabetic nephropathy biomarkers in the plasma peptidome by high‐throughput magnetic bead processing and MALDI‐TOF‐MS analysis
NZ593392A (en) Biomarker for detecting bladder cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16760417

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16760417

Country of ref document: EP

Kind code of ref document: A2